Roche looks to bring evidence-based medicine tech to India

MUMBAI: Swiss drug maker Roche is looking for startups in India that will help the company bring evidence-based medicine in India through its proprietary technology, according to the company’s newly appointed India head.

Lara Bezerra, Roche Managing Director (India), who moved from the troubled Venezuela market to India, told ET that as part of its long-term strategy the company can bring applications of Flatiron, a tech company that it acquired this year to India.

Flatiron Health is a market leader in oncology-specific electronic health record (EHR) software, as well as the curation and development of real-world evidence for cancer research.

Roche during the acquisition of the company in February said that with its large network of community oncology practices and academic medical centres across the US, Flatiron Health has created a technology platform designed to learn from the experience of every patient.

“When we are having this vision for India we realised that whatever you do in India you can’t do in short term. So we have to think something long term. So we are looking how should we bring Flatiron tech to India,” said Benzerra. “May be there is startup in India that can work with Flatiron so we are looking at all these options.”

Millions of patient profile is matched through this tech and the doctor is provided with the best possible outcomes that these kinds of patients have. So along with medical judgement the doctor has an option to lean into this data base too, explained V Simpson Emmanuel, Director, Market Access, Roche India.

  • Related Posts

    Dr Reddy’s delays semaglutide supplies due to API issue

    MUMBAI: Dr Reddy’s Laboratories’ plans to capitalize on the early generic semaglutide market have hit a setback after manufacturing issues delayed supplies of the blockbuster diabetes and weight-loss drug, forcing…

    India Tightens Rules On Alcohol-Containing Medicines

    New rules on alcohol in medicine: The Centre has brought oral medicines containing more than 12% ethyl alcohol and sold in bottles larger than 30 ml under Schedule H1 In…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Dr Reddy’s delays semaglutide supplies due to API issue

    Dr Reddy’s delays semaglutide supplies due to API issue

    India Tightens Rules On Alcohol-Containing Medicines

    India Tightens Rules On Alcohol-Containing Medicines

    One more held in spurious plasma racket; police say he supplied 12 boxes

    One more held in spurious plasma racket; police say he supplied 12 boxes

    Wegovy, Ozempic regain weight as Indian generics fall behind

    Wegovy, Ozempic regain weight as Indian generics fall behind

    Drug regulator orders fresh safety labels for five common antimicrobials

    Drug regulator orders fresh safety labels for five common antimicrobials

    Rajasthan recalls labour-inducing drug after quality test failure

    Rajasthan recalls labour-inducing drug after quality test failure